Abstract
Neuroblastoma (NB), the third most common paediatric cancer, accounts for 7% of paediatric malignancies and 10–15% of cancer-related deaths in children. Prognosis and tailored treatments are determined by several clinical and biological risk factors. These factors have been used to create risk classifiers that predict the probability of recurrence. The estimated 5-year survival rates for patients with non-high risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have continued to reduce therapy for patients with non-high risk neuroblastoma, including the most favourable subsets of patients, who are now often followed with observation approaches. In contrast, high-risk neuroblastoma patients are treated aggressively with chemotherapy, radiation, surgery, myeloablative and immunotherapies. Current prognostic factors used by most clinical trials cooperative groups and the International Risk Group (INRG) classification system include age, stage, histopathology, ploidy, status of MYCN and segmental chromosome aberrations (SCAs). In addition to these well-validated risk factors, research advances facilitated by large international collaborations and next generation sequencing (NGS) technologies have identified additional emerging prognostic factors at diagnosis and during treatment. These include specific genetic alterations of the ALK oncogene, aberrations of the telomerase pathway (including TERT fusions and ATRX mutations) and metastatic response. Standard prognostic factors together with these newer biomarkers will enable us to further refine risk categories as well as optimize treatment and enable precision medicine strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Irwin MS, Park JR. Neuroblastoma: pediatric paradigm for precision medicine. Pediatr Clin North Am. 2015;62:225–56.
Pinto NR, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–17. https://doi.org/10.1200/JCO.2014.59.4648.
Brodeur GM, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.
Cohn SL, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.
Cecchetto G, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23:8483–9.
Monclair T, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303.
Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer. 2008;50:965–9. https://doi.org/10.1002/pbc.21343.
Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol. 2004;26:791–6.
Schmidt ML, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children’s Cancer Group study. J Clin Oncol. 2000;18:1260–8.
George RE, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005;23:6466–73.
London WB, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23:6459–65.
Mosse YP, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61:627–35. https://doi.org/10.1002/pbc.24777.
Schmidt ML, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children’s Cancer Group study. J Clin Oncol. 2005;23:6474–80.
Schleiermacher G, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105:1940–8. https://doi.org/10.1038/bjc.2011.472.
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4.
Seeger RC, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–6.
Moreau LA, et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children’s Oncology Group study. Clin Cancer Res. 2006;12:5693–7.
Ambros PF, et al. International consensus for neuroblastoma molecular diagnostics: report from the international Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100:1471–82.
Campbell K, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children’s Oncology Group. Cancer. 2017;123:4224–35. https://doi.org/10.1002/cncr.30873.
Berbegall AP, et al. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene. 2016;35:1423–32. https://doi.org/10.1038/onc.2015.200.
Marrano P, Irwin MS, Thorner PS. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Genes Chromosomes Cancer. 2017;56:28–41. https://doi.org/10.1002/gcc.22398.
Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3:a014415. https://doi.org/10.1101/cshperspect.a014415.
Ruiz-Perez MV, Henley AB, Arsenian-Henriksson M. The MYCN protein in health and disease. Genes (Basel). 2017;8 https://doi.org/10.3390/genes8040113.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16:2985–95.
Zhu S, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012;21:362–73. https://doi.org/10.1016/j.ccr.2012.02.010.
Berry T, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22:117–30. https://doi.org/10.1016/j.ccr.2012.06.001.
Valentijn LJ, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A. 2012;109:19190–5. https://doi.org/10.1073/pnas.1208215109.
Puissant A, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3:308–23. https://doi.org/10.1158/2159-8290.CD-12-0418.
Gustafson WC, et al. Drugging MYCN through an allosteric transition in Aurora Kinase A. Cancer Cell. 2014;26:414–27. https://doi.org/10.1016/j.ccr.2014.07.015.
Brockmann M, et al. Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma. Cancer Cell. 2013;24:75–89. https://doi.org/10.1016/j.ccr.2013.05.005.
DuBois SG, et al. Phase I study of the Aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial. J Clin Oncol. 2016;34:1368–75. https://doi.org/10.1200/JCO.2015.65.4889.
Wang LL, et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children’s Oncology Group. Cancer. 2013;119:3718–26. https://doi.org/10.1002/cncr.28251.
Wang LL, et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study. Br J Cancer. 2015;113:57–63. https://doi.org/10.1038/bjc.2015.188.
Bagatell R, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009;27:365–70.
Vo KT, et al. Clinical, biological and prognostic differences based on primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. J Clin Oncol. 2014;32(28):3169–76.
Thompson D, et al. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group project. Cancer. 2016;122:935–45. https://doi.org/10.1002/cncr.29848.
Teshiba R, et al. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children’s Oncology Group. Pediatr Dev Pathol. 2014;17:441–9. https://doi.org/10.2350/14-06-1505-OA.1.
George RE, et al. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol. 2001;36:169–76. https://doi.org/10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U.
Shimada H, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–72.
Shimada H, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995;87:1470–6.
Bowman LC, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997;89:373–80.
Look AT, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:581–91.
Oppedal BR, Storm-Mathisen I, Lie SO, Brandtzaeg P. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer. 1988;62:772–80.
Janoueix-Lerosey I, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27:1026–33.
Attiyeh EF, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–53.
Brodeur GM, et al. Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human neuroblastomas. Prog Clin Biol Res. 1988;271:3–15.
Maris JM, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol. 2000;18:1888–99.
Mosse YP, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer. 2007;46:936–49. https://doi.org/10.1002/gcc.20477.
Guo C, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18:4948–57.
Tonini GP, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol. 1997;15:85–93.
De Bernardi B, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009;27:1034–40. https://doi.org/10.1200/JCO.2008.17.5877.
Minard V, et al. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology. Br J Cancer. 2000;83:973–9. https://doi.org/10.1054/bjoc.2000.1412.
Katzenstein HM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience—a pediatric oncology group study. J Clin Oncol. 1998;16:2007–17.
Baker DL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363:1313–23. https://doi.org/10.1056/NEJMoa1001527.
Rubie H, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol. 1997;15:1171–82. https://doi.org/10.1200/JCO.1997.15.3.1171.
Shimada H, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73:405–16.
Strother DR, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol. 2012;30:1842–8. https://doi.org/10.1200/JCO.2011.37.9990.
Meany HJ, et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014; https://doi.org/10.1002/pbc.25134.
Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311:231–5. https://doi.org/10.1056/NEJM198407263110405.
Park JR, et al. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985–93. https://doi.org/10.1002/pbc.24433.
Bown N, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–61.
Meddeb M, et al. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer. 1996;17:156–65. https://doi.org/10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3.
Caron H, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334:225–30.
Riley RD, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4–12.
Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006;12:3368–73. https://doi.org/10.1158/1078-0432.CCR-05-2495.
Schleiermacher G, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012;107:1418–22. https://doi.org/10.1038/bjc.2012.375.
Defferrari R, et al. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. Br J Cancer. 2015;112:290–5. https://doi.org/10.1038/bjc.2014.557.
Chicard M, et al. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin Cancer Res. 2016;22:5564–73. https://doi.org/10.1158/1078-0432.CCR-16-0500.
Van Roy N, et al. Shallow whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma patients. Clin Cancer Res. 2017;23:6305–14. https://doi.org/10.1158/1078-0432.CCR-17-0675.
Campbell BB, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042–1056 e1010. https://doi.org/10.1016/j.cell.2017.09.048.
Pugh TJ, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; https://doi.org/10.1038/ng.2529.
Molenaar JJ, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483:589–93. https://doi.org/10.1038/nature10910.
Sausen M, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45:12–7. https://doi.org/10.1038/ng.2493.
Bresler SC, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26:682–94. https://doi.org/10.1016/j.ccell.2014.09.019.
Suzuki M, et al. Treatment and outcome of adult-onset neuroblastoma. Int J Cancer. 2018; https://doi.org/10.1002/ijc.31399.
Cheung NK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307:1062–71. https://doi.org/10.1001/jama.2012.228.
Bellini A, et al. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res. 2015;21:4913–21. https://doi.org/10.1158/1078-0432.CCR-15-0423.
Schleiermacher G, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014; https://doi.org/10.1200/JCO.2013.54.0674.
Eleveld TF, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47:864–71. https://doi.org/10.1038/ng.3333.
Padovan-Merhar OM, et al. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet. 2016;12:e1006501. https://doi.org/10.1371/journal.pgen.1006501.
Schulte JH, et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res. 2011;17:5082–92. https://doi.org/10.1158/1078-0432.CCR-10-2809.
De Brouwer S, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010;16:4353–62. https://doi.org/10.1158/1078-0432.CCR-09-2660.
Duijkers FA, et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol. 2012;180:1223–31. https://doi.org/10.1016/j.ajpath.2011.12.003.
Bresler SC, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011;3:108ra114. https://doi.org/10.1126/scitranslmed.3002950.
Infarinato NR, et al. The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov. 2016;6:96–107. https://doi.org/10.1158/2159-8290.CD-15-1056.
Peifer M, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4. https://doi.org/10.1038/nature14980.
Valentijn LJ, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47:1411–4. https://doi.org/10.1038/ng.3438.
Hertwig F, Peifer M, Fischer M. Telomere maintenance is pivotal for high-risk neuroblastoma. Cell Cycle. 2016;15:311–2. https://doi.org/10.1080/15384101.2015.1125243.
Henson JD, et al. The C-Circle Assay for alternative-lengthening-of-telomeres activity. Methods. 2017;114:74–84. https://doi.org/10.1016/j.ymeth.2016.08.016.
Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine. Cancer Discov. 2015;5:82–95. https://doi.org/10.1158/2159-8290.CD-14-0609.
Flynn RL, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015;347:273–7. https://doi.org/10.1126/science.1257216.
Vermeulen J, De Preter K, Laureys G, Speleman F, Vandesompele J. 59-Gene prognostic signature sub-stratifies high-risk neuroblastoma patients. Lancet Oncol. 2009;10:1030. https://doi.org/10.1016/S1470-2045(09)70325-0, S1470-2045(09)70325-0 [pii].
De Preter K, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res. 2010;16:1532–41.
Oberthuer A, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006;24:5070–8.
Oberthuer A, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol. 2010;28:3506–15. https://doi.org/10.1200/JCO.2009.27.3367, JCO.2009.27.3367 [pii].
Garcia I, et al. A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin Cancer Res. 2012–2023;18:2012. https://doi.org/10.1158/1078-0432.CCR-11-2483.
Asgharzadeh S, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006;98:1193–203. https://doi.org/10.1093/jnci/djj330., 98/17/1193 [pii].
Asgharzadeh S, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30:3525–32. https://doi.org/10.1200/JCO.2011.40.9169.
Hallett RM, Seong AB, Kaplan DR, Irwin MS. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Mol Oncol. 2016;10:1461–72. https://doi.org/10.1016/j.molonc.2016.07.012.
Oberthuer A, et al. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res. 2015;21:1904–15. https://doi.org/10.1158/1078-0432.CCR-14-0817.
Buckley PG, et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin Cancer Res. 2010;16:2971–8. https://doi.org/10.1158/1078-0432.CCR-09-3215, 1078-0432.CCR-09-3215 [pii].
Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007;67:976–83. https://doi.org/10.1158/0008-5472.CAN-06-3667.
De Preter K, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res. 2011;17:7684–92. https://doi.org/10.1158/1078-0432.CCR-11-0610.
Yanik GA, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med. 2013; https://doi.org/10.2967/jnumed.112.112334.
Matthay KK, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486–91. https://doi.org/10.1200/JCO.2003.09.122.
Suc A, et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer. 1996;77:805–11.
Ady N, et al. A new 123I-MIBG whole body scan scoring method—application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31A:256–61.
Ladenstein R, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292–305. https://doi.org/10.1007/s00259-017-3829-7.
Brownhill SC, Burchill SA. PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers – focus on neuroblastoma. Pract Lab Med. 2017;7:41–4. https://doi.org/10.1016/j.plabm.2016.04.003.
Viprey VF, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. 2014;32:1074–83. https://doi.org/10.1200/JCO.2013.53.3604.
Corrias MV, et al. A novel syngeneic murine model for thoracic neuroblastoma obtained by intramediastinal injection of tumor cells. Cancer Detect Prev. 2002;26:468–75.
Kreissman SG, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999–1008. https://doi.org/10.1016/S1470-2045(13)70309-7.
Marachelian A, et al. Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. Clin Cancer Res. 2017;23:5374–83. https://doi.org/10.1158/1078-0432.CCR-16-2647.
Alvarado CS, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2000;22:197–205.
Perez CA, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18:18–26.
Simon T, Spitz R, Hero B, Berthold F, Faldum A. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Cancer Lett. 2006;237:215–22. https://doi.org/10.1016/j.canlet.2005.06.001.
Nuchtern JG, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg. 2012;256:573–80. https://doi.org/10.1097/SLA.0b013e31826cbbbd.
Hero B, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26:1504–10. https://doi.org/10.1200/JCO.2007.12.3349.
Kushner BH, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol. 1996;14:373–81.
Ladenstein R, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500–14. https://doi.org/10.1016/S1470-2045(17)30070-0.
Yu A, Gilman AL, Ozkaynak MF. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GMCSF and IL2 as immunotherapy following dose intensive chemotherapy for high risk neuroblsatoma: Children’s Oncology Group (COG) study ANBL0032. J Clin Oncol. 2009;27
Depuydt P, et al. Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients. J Natl Cancer Inst. 2018; https://doi.org/10.1093/jnci/djy022.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Irwin, M.S. (2020). Prognostic Factors and Risk Stratification. In: Sarnacki, S., Pio, L. (eds) Neuroblastoma. Springer, Cham. https://doi.org/10.1007/978-3-030-18396-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-18396-7_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-18395-0
Online ISBN: 978-3-030-18396-7
eBook Packages: MedicineMedicine (R0)